Trial Profile

Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMC CS4 (Primary)
Indications Advanced breast cancer; Prostate cancer
Focus Biomarker; Pharmacodynamics; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

26 Aug 2020 Results published in the Clinical Cancer Research
04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
15 May 2019 According to a Eli Lilly media release, data from this trial will be presented at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com